Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001193125-26-122268

Chief Financial Officer sold 3,708 shares at $46.78 ($173,460)

  • Chief Financial Officer acquired 6,250 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Prasad Raju · Chief Financial Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2026-03-20 Exercise or conversion : show line 1 in the form +6,250 19,273 D
2026-03-23 Sale : show line 2 in the form −3,708 $46.78 $173,460 15,565 D
Open-market sales · 3,708 sh · avg $46.78 · $173,460

Table II: Derivative

3 lines
Date Transaction Shares Owned after D/I
2026-03-20 Grant or award : show line 3 in the form Stock Option (Right to Buy) +38,499 38,499 D
2026-03-20 Grant or award : show line 4 in the form Restricted Stock Units +27,500 27,500 D
2026-03-20 Exercise or conversion : show line 5 in the form Restricted Stock Units −6,250 12,500 D
Loading xslF345X06/ownership.xml…